A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients.

Trial Profile

A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Inborn urea cycle disorders
  • Focus Therapeutic Use
  • Sponsors Promethera Biosciences
  • Most Recent Events

    • 11 Mar 2017 This trial has been discontinued in Poland as per European Clinical Trials Database record.
    • 15 Oct 2016 According to Promethera Biosciences media release, company receives approval in Belgium to enroll patients in the study.
    • 26 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top